Thermo Fisher Scientific Inc. $TMO Shares Sold by North Star Investment Management Corp.

North Star Investment Management Corp. lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,424 shares of the medical research company’s stock after selling 30 shares during the period. North Star Investment Management Corp.’s holdings in Thermo Fisher Scientific were worth $4,227,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC grew its holdings in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares in the last quarter. Ameriflex Group Inc. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $30,000. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $30,000. Keystone Global Partners LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $31,000. Finally, IMA Advisory Services Inc. acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $35,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.4%

Shares of Thermo Fisher Scientific stock opened at $467.91 on Thursday. The company has a market cap of $176.69 billion, a P/E ratio of 27.06, a PEG ratio of 2.55 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The firm has a fifty day moving average of $475.04 and a two-hundred day moving average of $448.83.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, September 7th. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a report on Thursday, July 24th. Barclays upgraded shares of Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $490.00 to $550.00 in a research report on Thursday, September 11th. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target for the company in a research report on Friday, July 11th. Finally, Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Sixteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $588.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.